ABSTRACT
(1) Background: In Italy, about one fourth of all schoolchildren experience a trauma to the permanent dentition. Management of avulsion trauma is challenging and requires adherence to clinical protocols. The aim of this study was to investigate the management knowledge of avulsed teeth among Italian dentists and to promote the guidelines' dissemination through the use of new social media. (2) Methods: The survey was carried out during the COVID-19 lockdown in Italy (March-May 2020). The questionnaire was sent anonymously to a total of 600 dentists. The questionnaire consisted of two parts. Part A-demographic and professional data and Part B-management of traumatic avulsion. (3) Results: The response rate was 50.6% and the mean fraction of correct responses was 0.524. Issues related to the therapeutic management of avulsed teeth were shown to be not well understood by the respondents. Professionals with qualifications in dentistry and those who declared to know the guidelines responded better, while other demographic and professional factors were insignificant. (4) Conclusions: Italian dentists' knowledge of the management of avulsion trauma should be improved. Educational programs and campaigns must be undertaken to improve their awareness and adherence to the Italian and international guidelines.
Subject(s)
Clinical Competence , Dentists , Health Knowledge, Attitudes, Practice , Tooth Avulsion/therapy , COVID-19 , Child , Communicable Disease Control , Humans , Italy , Surveys and QuestionnairesSubject(s)
DNA-Binding Proteins/genetics , Karyotype , Myeloproliferative Disorders/diagnosis , Myeloproliferative Disorders/genetics , Oncogene Proteins, Fusion/genetics , Receptor, Platelet-Derived Growth Factor beta/genetics , Adult , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Biopsy , Bone Marrow/pathology , DNA Mutational Analysis , Humans , Leukocyte Count , Male , Myeloproliferative Disorders/drug therapy , UltrasonographySubject(s)
Kruppel-Like Transcription Factors/genetics , Lymphoma, B-Cell, Marginal Zone/genetics , Mutation , Splenic Neoplasms/genetics , Alleles , Cell Transformation, Neoplastic , DNA Mutational Analysis , Gene Deletion , Gene Dosage , HEK293 Cells , Humans , In Situ Hybridization, Fluorescence , Jurkat Cells , Polymorphism, Single NucleotideABSTRACT
We conducted a phase II, noncomparative, open-label, multicenter GIMEMA (Gruppo Italiano Malattie EMatologiche dell'Adulto) study (CLL0809) to assess the efficacy and safety of bendamustine in combination with ofatumumab (BendOfa) in relapsed/refractory chronic lymphocytic leukemia (CLL). Forty-seven patients from 14 centers were evaluated. Therapy consisted of bendamustine (70 mg/m(2)) for 2 consecutive days every 28 days, and ofatumumab 300 mg on day 1 and 1000 mg on day 8 during the first cycle, and 1000 mg on day 1 subsequently. Treatment was administered up to six cycles. The overall response rate (ORR), as per intention-to-treat analysis, was 72.3% (95% confidence of interval (CI), 57-84%), with 17% complete responses. After a median follow-up of 24.2 months, the overall survival was 83.6% (95% CI, 73.0-95.7%) and the progression-free survival (PFS) was 49.6% (95% CI, 35.9-68.6%). The median PFS was 23.6 months. Univariate and multivariate analyses were used to identify clinical and biological characteristics associated with ORR and PFS. Myelosuppression was the most common toxicity; grade ≥3 neutropenia was observed in 61.7% of patients; however, grade ≥3 infections occurred in 6% of patients. BendOfa is feasible and effective in relapsed/refractory CLL patients, including patients with high-risk clinical and biological features.
Subject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Leukemia, Lymphocytic, Chronic, B-Cell/drug therapy , Aged , Antibodies, Monoclonal/administration & dosage , Antibodies, Monoclonal, Humanized , Bendamustine Hydrochloride , Female , Humans , Leukemia, Lymphocytic, Chronic, B-Cell/pathology , Male , Nitrogen Mustard Compounds/administration & dosage , RecurrenceABSTRACT
BACKGROUND: Genomic complexity can predict the clinical course of patients affected by chronic lymphocytic leukemia (CLL) with a normal FISH. However, large studies are still lacking. Here, we analyzed a large series of CLL patients and also carried out the so far largest comparison of FISH versus single-nucleotide polymorphism (SNP) array in this disease. PATIENTS AND METHODS: SNP-array data were derived from a previously reported dataset. RESULTS: Seventy-seven of 329 CLL patients (23%) presented with a normal FISH. At least one large (>5 Mb) genomic aberration was detected by SNP array in 17 of 77 patients (22%); this finding significantly affected TTT. There was no correlation with the presence of TP53 mutations. In multivariate analysis, including age, Binet stage, IGHV genes mutational status and large genomic lesion, the latter three factors emerged as independent prognosticators. The concordance between FISH and SNP array varied between 84 and 97%, depending on the specific genomic locus investigated. CONCLUSIONS: SNP array detected additional large genomic aberrations not covered by the standard FISH panel predicting the outcome of CLL patients.
Subject(s)
Chromosome Aberrations , Leukemia, Lymphocytic, Chronic, B-Cell/genetics , Female , Genotype , Humans , Immunoglobulin Heavy Chains/genetics , Immunoglobulin Variable Region/genetics , In Situ Hybridization, Fluorescence , Male , Middle Aged , Multivariate Analysis , Oligonucleotide Array Sequence Analysis , Polymorphism, Single Nucleotide , Prognosis , Tumor Suppressor Protein p53/geneticsSubject(s)
Antineoplastic Agents/pharmacology , Hydroxamic Acids/pharmacology , Leukemia, Megakaryoblastic, Acute/drug therapy , Leukemia, Megakaryoblastic, Acute/metabolism , NF-kappa B/metabolism , Wnt Proteins/metabolism , Apoptosis/drug effects , Biomarkers, Tumor/genetics , Biomarkers, Tumor/metabolism , Cell Cycle/drug effects , Cell Proliferation/drug effects , Electrophoretic Mobility Shift Assay , Flow Cytometry , Gene Expression Profiling , Histone Deacetylase Inhibitors , Humans , Leukemia, Megakaryoblastic, Acute/pathology , NF-kappa B/genetics , Oligonucleotide Array Sequence Analysis , Signal Transduction , Tumor Cells, Cultured , VorinostatSubject(s)
Antineoplastic Agents/pharmacology , Boronic Acids/pharmacology , Enzyme Inhibitors/pharmacology , Gene Expression Regulation, Leukemic/drug effects , Genes, Wilms Tumor/drug effects , Hydroxamic Acids/pharmacology , Neoplasm Proteins/biosynthesis , Pyrazines/pharmacology , WT1 Proteins/biosynthesis , Bortezomib , Cell Line, Tumor/metabolism , Down-Regulation/drug effects , Drug Screening Assays, Antitumor , Drug Synergism , Humans , Leukemia, Megakaryoblastic, Acute/pathology , Leukemia, Myelomonocytic, Chronic/pathology , Megakaryocytes/drug effects , Megakaryocytes/metabolism , VorinostatABSTRACT
Acute promyelocytic leukaemia (APL) is a well-defined disease characterized by a typical morphology of leukaemic cells, the presence of t(15;17) translocation and the unique sensitivity to the differentiating effect of all-trans retinoic acid. Nevertheless, some aspects are variable among APL patients, with differences substantially related to morphological variants, peripheral leukocytes count, the presence of a disseminated intravascular coagulopathy, different PML/RARalpha isoforms (long, variable or short) and Fms-like tyrosine kinase 3 (Flt3) mutations. In order to better define this variability, we investigated the gene expression profiles of 18 APL cases revealing, besides a high uniformity in gene expression pattern, the presence of few robust differences among patients able to identify, by an unsupervised analysis, two major clusters of patients characterized by different phenotypes (hypogranular M3v vs classical M3) and by the presence or absence of Flt3 internal tandem duplications (ITDs). Further supervised analysis confirmed that Flt3 status was the APL parameter best associated with these two subgroups. We identified, between Flt3 wild-type and Flt3-ITDs subsets, 147 differentially expressed genes that were involved in the cytoskeleton organization, in the cell adhesion and migration, in the proliferation and the coagulation/inflammation pathways as well as in differentiation and myeloid granules constitution suggesting a role of Flt3 mutations in the pathogenesis and clinical manifestations of APL.
Subject(s)
Gene Expression Profiling , Leukemia, Promyelocytic, Acute/genetics , Multigene Family , fms-Like Tyrosine Kinase 3/genetics , Adult , Aged , Aged, 80 and over , Cluster Analysis , Exons , Female , Humans , Leukemia, Promyelocytic, Acute/classification , Leukemia, Promyelocytic, Acute/diagnosis , Male , Middle Aged , Mutation , PhenotypeSubject(s)
Cell Transformation, Neoplastic/pathology , Leukemia, Lymphocytic, Chronic, B-Cell/pathology , Leukemia, Myelogenous, Chronic, BCR-ABL Positive/pathology , Neoplasms, Second Primary/etiology , Cell Lineage/genetics , Cell Lineage/immunology , Cell Transformation, Neoplastic/genetics , Cell Transformation, Neoplastic/immunology , Clone Cells/pathology , Cytogenetic Analysis , Humans , Immunophenotyping , Leukemia, Lymphocytic, Chronic, B-Cell/etiology , Leukemia, Myelogenous, Chronic, BCR-ABL Positive/etiology , Lymphocytes/pathology , Middle Aged , Myeloid Cells/pathology , Neoplasms, Second Primary/pathologyABSTRACT
Seventy-two patients with non-Hodgkin's lymphoma were evaluated for the presence of molecular markers (IgH, bcl-1, bcl-2 rearrangement) on bone marrow, at diagnosis and after PBSCT, and on harvests in order to find a possible predictive role of minimal residual disease on treatment outcome. At diagnosis, 41 (59%) out of 69 available bone marrows showed molecular involvement. Fifty-six percent of leukaphereses were involved, mainly indolent lymphoma (P = 0.001) or advanced disease (P = 0.01). Ex vivo purging cleared only one stem collection out of 31 PCR-positive leukaphereses. Aggressive lymphomas showed both a longer overall survival (OS) (P = 0.03) and relapse-free survival RFS (P = 0.02) when transplanted with unpurged stem cells, whereas indolent NHL survival was not influenced by ex vivo purging. Twenty out of 26 samples taken during follow-up had bone marrow involvement at diagnosis. Of these, 15 cleared their bone marrow; both OS and RFS were significantly longer in the PCR-negative cases (P = 0.05 and P = 0.005). At 1 year after PBSCT, 75% of patients were PCR negative, with 50% molecular remissions; the relapse rate was 55% for patients still PCR positive vs 29% for those who were PCR negative. Thus, after high-dose chemotherapy, close molecular monitoring of MRD using qualitative PCR techniques seems to represent a reliable prognostic indicator.
Subject(s)
Biomarkers, Tumor/analysis , Bone Marrow/chemistry , Cyclin D1/analysis , Immunoglobulin Heavy Chains/analysis , Lymphoma, Non-Hodgkin/chemistry , Neoplasm Proteins/analysis , Proto-Oncogene Proteins c-bcl-2/analysis , Adolescent , Adult , Antineoplastic Combined Chemotherapy Protocols/administration & dosage , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Bone Marrow Purging , Combined Modality Therapy , Cyclin D1/genetics , Cyclophosphamide/administration & dosage , Disease-Free Survival , Doxorubicin/administration & dosage , Female , Follow-Up Studies , Genes, bcl-2 , Humans , Immunoglobulin Heavy Chains/genetics , Leukapheresis , Life Tables , Lymphoma, Non-Hodgkin/drug therapy , Lymphoma, Non-Hodgkin/mortality , Lymphoma, Non-Hodgkin/pathology , Lymphoma, Non-Hodgkin/therapy , Male , Middle Aged , Neoplasm, Residual , Polymerase Chain Reaction , Predictive Value of Tests , Prednisone/administration & dosage , Proto-Oncogene Proteins c-bcl-2/genetics , Retrospective Studies , Survival Analysis , Treatment Outcome , Vincristine/administration & dosageABSTRACT
Nodal marginal zone B-cell lymphoma (NMZL) is actually considered as a distinct entity that must be distinguished from extra-nodal and splenic marginal zone lymphomas. To define the cell origin and the role of antigen stimulation we determined the nucleotide sequence of the tumor-related immunoglobulin heavy chain variable genes in 10 cases of NMZL. The results were also evaluated on the basis of the presence of chronic hepatitis C virus (HCV) infection. All 10 cases harbored VH somatic mutations with a sequence homology compared to the closest germline gene, ranging from 83.33 to 98.28%. Interestingly, different VH segments were preferentially used in HCV-positive and HCV-negative patients: three of five HCV-negative NMZLs used a VH4-34 segment joined with different D and JH segments whereas three of five HCV-positive NMZLs used a VH1-69 gene joined with a D3-22 and a JH4 segment, with very strong similarities in the CDR3s among the three different cases. These data indicate: 1) NMZL is derived from B cells that have experienced the germinal center reaction; 2) the preferential usage of a VH1-69 segment in the majority of the HCV-positive NMZL cases with similar CDR3s suggests the presence of a common antigen, probably a HCV antigen epitope, involved in the B-cell selection; and 3) the use of a VH4-34 segment suggests a role of yet unknown B-cell superantigen(s) in the selection of tumor B-cell precursors in HCV-negative NMZL.
Subject(s)
Hepacivirus/isolation & purification , Immunoglobulin Heavy Chains/genetics , Immunoglobulin Variable Region/genetics , Immunoglobulins/genetics , Lymphoma, B-Cell/genetics , Lymphoma, B-Cell/virology , Mutation/physiology , Base Sequence/genetics , Gene Rearrangement , Humans , Molecular Sequence Data , Mutation/genetics , Polymerase Chain ReactionSubject(s)
Fusion Proteins, bcr-abl/genetics , Thrombocythemia, Essential/genetics , Acute Disease , Adult , Aged , Aged, 80 and over , Female , Humans , Italy/epidemiology , Leukemia, Myeloid/genetics , Male , Middle Aged , Philadelphia Chromosome , Reverse Transcriptase Polymerase Chain Reaction , Sensitivity and Specificity , Thrombocythemia, Essential/blood , Thrombocythemia, Essential/epidemiologyABSTRACT
BACKGROUND: Human herpesvirus 8 (HHV-8) infection has been linked to the development of Kaposi's sarcoma and to rare lymphoproliferative disorders. METHODS: We used molecular methods, serologic methods, in situ hybridization, and immunohistochemical analyses to study HHV-8 infection in association with nonmalignant illnesses in three patients after transplantation. RESULTS: Primary HHV-8 infections developed in two patients four months after each received a kidney from the same HHV-8-seropositive cadaveric donor. Seroconversion and viremia occurred coincidentally with disseminated Kaposi's sarcoma in one patient and with an acute syndrome of fever, splenomegaly, cytopenia, and marrow failure with plasmacytosis in the other patient. HHV-8 latent nuclear antigen was present in immature progenitor cells from the aplastic marrow of the latter patient. Identification of the highly variable K1 gene sequence of the HHV-8 genome in both the donor's peripheral-blood cells and the recipients' serum confirmed that transmission had occurred. HHV-8 viremia also occurred after autologous peripheral-blood stem-cell transplantation in an HHV-8-seropositive patient with non-Hodgkin's lymphoma. Reactivation of the infection was associated with the development of fever and marrow aplasia with plasmacytosis; there was no evidence of other infections. HHV-8 transcripts and latent nuclear antigen were expressed in the aplastic marrow but not in two normal marrow samples obtained before transplantation. CONCLUSIONS: Primary HHV-8 infection and reactivation of infection may be associated with nonneoplastic complications in immunosuppressed patients.
Subject(s)
Bone Marrow Diseases/etiology , Disease Transmission, Infectious , Hematopoietic Stem Cell Transplantation/adverse effects , Herpesviridae Infections/transmission , Herpesvirus 8, Human/isolation & purification , Kidney Transplantation/adverse effects , Sarcoma, Kaposi/etiology , Adult , Antibodies, Viral/blood , Blood Cell Count , Bone Marrow/virology , Bone Marrow Diseases/blood , Bone Marrow Diseases/virology , Fatal Outcome , Genome, Viral , Herpesviridae Infections/etiology , Herpesviridae Infections/virology , Herpesvirus 8, Human/genetics , Herpesvirus 8, Human/immunology , Humans , Immunocompromised Host , Male , Middle Aged , Sarcoma, Kaposi/virology , Viremia/etiology , Virus ActivationABSTRACT
In transplant patients, Kaposi sarcoma (KS)-associated herpesvirus or human herpesvirus-8 (HHV-8) infection is associated with the development of KS, primary effusion lymphoma and Castleman disease. Whether HHV-8 is either reactivated in the recipient or transmitted by the donor has been investigated so far only by serologic studies. Thus, we addressed the issue of HHV-8 transmission in the transplantation setting by molecular methods. We exploited the high level variability of the orf-K1 gene and the polymorphism of the orf-73 gene of the HHV-8 genome to assess the genetic relatedness of the HHV-8 strains identified in the posttransplant KS lesions that developed, simultaneously, 20 months after transplantation, in 2 recipients of twin kidneys from the same cadaver donor. The 100% identity of nucleotide sequence of the most variable viral region and the presence of the same, single orf-73 type in both patients provides strong molecular evidence of organ-related transmission of HHV-8 in the setting of transplantation.
Subject(s)
Herpesvirus 8, Human/isolation & purification , Kidney Transplantation , Postoperative Complications , Sarcoma, Kaposi/virology , Base Sequence , Female , Genotype , Herpesvirus 8, Human/genetics , Herpesvirus 8, Human/physiology , Humans , Middle Aged , Molecular Sequence Data , Sequence Alignment , Virus ActivationABSTRACT
Fever, cutaneous rash, and hepatitis-for which an infectious cause was suspected-developed in an Italian patient with non-Hodgkin lymphoma after autologous peripheral blood stem cell (PBSC) transplantation. Polymerase chain reaction (PCR) with degenerate primers for the highly conserved DNA polymerase gene of herpesviruses detected herpesvirus sequences 100% identical to human herpesvirus-8 (HHV-8) in serial cell-free serum samples, collected immediately before or concomitant with the occurrence of clinical symptoms; no other common infections were documented. The presence of the HHV-8 genome (clade C) was confirmed by PCR with HHV-8-specific primers for orf 26 and orf-K1. HHV-8 viremia was undetectable either before transplantation or when the patient was clinically asymptomatic. Semiquantitative PCR analysis showed variations of the viral load correlating with the clinical status. Anti-HHV-8 antibodies were detected before and after transplantation by an immunofluorescence assay for lytic antigens. Active HHV-8 infection may be associated with nonmalignant illness after PBSC/bone marrow transplantation.